Marija Djordjic Crnogorac

Dr. Marija Djordjic Crnogorac

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2011 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
MZMartin Zehl
Martin Zehl
CBChristina Braunberger
Christina Braunberger
JCJürgen Conrad
Jürgen Conrad
MCMarija Djordjic Crnogorac
Marija Djordjic Crnogorac
SKStanimira Krasteva
Stanimira Krasteva
Liselotte KrennLiselotte Krenn
Liselotte Krenn

15 January 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MJMarko Jevrić
Marko Jevrić
IMIvana Z. Matić
Ivana Z. Matić
AKAna Krivokuca
Ana Krivokuca
MCMarija Djordjic Crnogorac
Marija Djordjic Crnogorac
IBIrina Besu
Irina Besu
TSTatjana Stanojkovic
Tatjana Stanojkovic
The aim of this study was to evaluate the prognostic potential of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) tumor tissue levels and examine the association between these biomarkers and classical prognostic factors in early node-negative luminal breast cancer patients. The clinical value of 4G/5G variants of PAI-1 gene was evaluated. This study involved 81 node-negative, estrogen receptor-positive and/or progesterone receptor-positive and human epidermal growth factor receptor 2-negative operable breast cancer patients who underwent radical surgical resection and received adjuvant endocrine therapy. Determination of uPA and PAI-1 concentrations in the breast cancer tissue extracts was performed using FEMTELLE® uPA/PAI-1 ELISA. An insertion (5G)/deletion (4G) polymorphism at position − 675 of the PAI-1 gene was detected by PCR-RFLP analysis. Our research showed that patients with uPA tumor tissue levels higher than 3 ng/mg of protein had significantly reduced disease-free survival (DFS) and overall survival (OS) when compared to patients with uPA tumor tissue levels lower or equal to 3 ng/mg of protein. Patients with PAI-1 tumor tissue levels higher than 14 ng/mg of protein had significantly decreased OS in comparison with patients with PAI-1 tumor tissue levels lower or equal to 14 ng/mg of protein. ROC analysis confirmed the uPA and PAI-1 discriminative potential for the presence/absence of relevant events in these patients and resulted in higher cut-off values (5.65 ng/mg of protein for uPA and 27.10 ng/mg of protein for PAI-1) than standard reference cut-off values for both biomarkers. The prognostic importance of uPA and PAI-1 ROC cut-off values was confirmed by the impact of uPA higher than 5.65 ng/mg of protein and PAI-1 higher than 27.10 ng/mg of protein on poorer DFS, OS and event-free survival (EFS). We observed that patients with dominant allele in PAI-1 genotype (heterozygote and dominant homozygote, − 675 4G/5G and − 675 5G/5G) had significantly increased DFS, OS and EFS when compared with patients with recessive homozygote genotype (− 675 4G/4G). Our study indicates that uPA and PAI-1 tumor tissue levels and 4G/5G variants of PAI-1 gene might be of prognostic significance in early node-negative luminal HER2-negative breast cancer patients treated with adjuvant endocrine therapy.

1 May 2019 in Bioorganic Chemistry
Verified
Journal Article
Closed access
NJNenad Janković
Nenad Janković
JRJovana Trifunović Ristovski
Jovana Trifunović Ristovski
MVMilan Vranes
Milan Vranes
ATAleksandar Tot
Aleksandar Tot
JPJelena M. Petronijević
Jelena M. Petronijević
ZBZorica Bugarčić
Zorica Bugarčić

21 August 2012 in BMC Immunology
Verified
Journal Article
Open access
PDF file
IMIvana Z Matić
Ivana Z Matić
MCMarija Djordjic Crnogorac
Marija Djordjic Crnogorac
Nadja Grozdanic StanisavljevicNadja Grozdanic Stanisavljevic
Nadja Grozdanic Stanisavljevic
Ana DamjanovicAna Damjanovic
Ana Damjanovic
BKBranka Kolundžija
Branka Kolundžija
ZJZorica D Juranić
Zorica D Juranić
Background: Dipeptidyl peptidase IV, a multifunctional serine protease, is implicated in regulation of malignant transformation, promotion and further progression of cancer, exerting tumor-suppressing or even completely opposite - tumor-promoting activities.The aim of present research was to determine the serum DPPIV activity, as well as the percentages of CD26+ lymphocytes, CD26+ overall white blood cells and the mean fluorescence intensity of CD26 expression on lymphocytes in patients with melanoma, people with vitiligo and in healthy controls.Methods: The activity of DPPIV in serum was determined by colorimetric test. Expression of DPPIV (as CD26) on immunocompetent peripheral white blood cells was done using flow cytometry analysis.Results: Data from our study show for the first time statistically significant decrease: in the serum DPPIV activity, in the percentage of CD26+ overall white blood cells and in the percentage of lymphocytes in patients with melanoma in comparison to healthy control people. In addition, significantly lower serum DPPIV activity was found in the group of patients with melanoma in relation to people with vitiligo too.Conclusion: This study indicates the need for exploring the cause and the importance of the disturbances in the serum DPPIV activity and in the CD26 expression on immunocompetent cells in complex molecular mechanisms underlying the development and progression of melanoma.

24 June 2016 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
PDF file
MGMilica Grujic
Milica Grujic
IMIvana Z. Matic
Ivana Z. Matic
MCMarija Djordjic Crnogorac
Marija Djordjic Crnogorac
AVAna Damjanovic Velickovic
Ana Damjanovic Velickovic
BKBranka Kolundzija
Branka Kolundzija
NDNemanja Damjanov
Nemanja Damjanov
Dipeptidyl peptidase IV (DPPIV/CD26) plays an important role in T cell activation and immune regulation, however the role of this enzyme in early rheumatoid arthritis (eRA) has not been clearly defined. The aim of this study was to determine the serum activity of DPPIV, its expression on peripheral blood mononuclear cells (PBMC) and to examine possible correlations with disease activity (DAS28) in untreated patients with eRA. The study included 50 patients newly diagnosed with RA, who had not received any corticosteroid or disease modifying antirheumatic drugs (DMARD) therapy and whose conventional radiographs of hands and feet showed no structural damage. The control group consisted of 40 healthy volunteers. Also, 30 patients with chronic RA (cRA) were examined. The serum activity of DPPIV was determined by the direct photometric method, while expression of CD26 on PBMC was determined using flow cytometry. Decreased DPPIV serum activity was detected in patients with eRA and cRA compared to the control group (p=0.024, p<0.0001, respectively). Although, the percentage of overall CD26+ white blood cells (WBC) was significantly decreased in eRA patients (p<0.001), the percentage of CD26+ lymphocytes and monocytes and mean fluorescence intensity of CD26 on these cells in eRA patients showed no significant difference compared to healthy volunteers. DAS28 showed no significant correlation with CD26 expression or DPPIV serum activity, but a significant inverse correlation between the duration of symptoms and DPPIV serum activity was observed. Our results show that a decrease in DPPIV serum activity, but not CD26 expression, is present in an early stage of rheumatoid arthritis.

11 February 2022 in Journal of Molecular Structure
Verified
Journal Article
Closed access
EMEmilija Milović
Emilija Milović
JPJelena Petronijević
Jelena Petronijević
NJNenad Joksimović
Nenad Joksimović
MBMilan Beljkaš
Milan Beljkaš
Dusan RuzicDusan Ruzic
Dusan Ruzic
NJNenad Janković
Nenad Janković